-
Zytiga OKed as prostate cancer treatment
HORSHAM, Pa. — The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.
Centocor Ortho Biotech, J&J’s biotech subsidiary, announced Thursday the approval of Zytiga (abiraterone acetate), a daily pill for use in combination with the corticosteroid prednisone for treating castration-resistant prostate cancer that has spread to other parts of the body in men who have received prior chemotherapy with Sanofi-Aventis’ Taxotere (docetaxel).
-
Report: Specialty pharmaceutical distributors helped industry save billions
ARLINGTON, Va. — Distributors of specialty drugs save the healthcare industry an estimated $3.5 billion per year by using extensive measures to ensure safe delivery, according to a new report by the Center for Healthcare Supply Chain Research, the research foundation of the Healthcare Distribution Management Association.